Compare Funko Inc (FNKO) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Funko Inc vs TG Therapeutics Inc — how do they compare? Funko Inc trades at $5.73 (market cap $315.21M), while TG Therapeutics Inc trades at $54.95 (market cap $8.64B). The key difference: TG Therapeutics Inc is far larger — about 27.4× Funko Inc's market cap. Which is the better fit depends on your goals.
| FNKO | TGTX | |
|---|---|---|
Market Cap | $315.21M | $8.64B |
Sector | Consumer Staples | Health |
52-Week High | $5.88 | $59.06 |
52-Week Low | $2.46 | $26.39 |
Enterprise Value | $560.25M | $8.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNKO trades at $5.785, up 4.23% today, with a bullish technical signal from moving averages. The stock shows improving revenue trends, with Q1 2026 sales reaching $200.9M, beating expectations, though net income remains negative. Analyst consensus is split between Buy and Hold, with no Sell ratings. Recent news highlights new product launches and strong collectibles demand, supporting a positive sentiment shift.
Outlook: FNKO presents a speculative opportunity with recent earnings beats and revenue growth, but risks include persistent net losses and high debt. Investors should weigh the bullish technicals and product momentum against fundamental weaknesses in profitability and cash flow volatility.
TG Therapeutics (TGTX) trades at $55.19, up 0.55% on the day, with a bullish technical signal from moving averages. The company shows strong profitability with a 65.95% net income margin and 112.6% ROE, though recent quarterly EPS has missed expectations. Positive clinical trial news for Briumvi in multiple sclerosis and schizophrenia is driving investor optimism and media coverage.
The outlook is supported by robust revenue growth and pipeline expansion, but risks include clinical trial execution and recent earnings volatility. Analysts are predominantly bullish with an 84.6% buy rating, though the consensus price target of $48.50 sits below the current price, suggesting potential near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
